Candel Therapeutics (CADL) Interest Expenses (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Interest Expenses data on file, last reported at $577000.0 in Q4 2025.

• For the quarter ending Q4 2025, Interest Expenses rose 507.37% year-over-year to $577000.0; the trailing twelve-month figure through Dec 2025 stood at $1.9 million (down 4.68% YoY), and the FY2025 full-year result was $65.3 million, up 136.49% from the prior year.
• Interest Expenses retreated to $577000.0 in Q4 2025, from $11.4 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $29.2 million in Q1 2022 to a low of $52000.0 in Q4 2022.
• A 5-year average of $8.0 million and a median of $669000.0 in 2023 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses sank 99.72% in 2022 and surged 2933.78% in 2024, its largest moves.
• Tracing CADL's Interest Expenses over 5 years: stood at $18.5 million in 2021, then slumped by 99.72% to $52000.0 in 2022, then jumped by 969.23% to $556000.0 in 2023, then sank by 82.91% to $95000.0 in 2024, then soared by 507.37% to $577000.0 in 2025.
• Business Quant data shows CADL's Interest Expenses at $577000.0 in Q4 2025, $11.4 million in Q3 2025, and $11.3 million in Q2 2025.